Ufur is approved for treatment of stomach cancer, breast cancer, and colon cancer.

Oral tegafur has offered hope of a more convenient method of administering 5-fluorouracil, and the minimal hematologic toxicity observed with oral tegafur has suggested its use in combination with other myelosuppressive agents without the need for significant dose reduction. Uracil mustard is of value in the palliative treatment of certain neoplasms such as chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and chronic myelogenous leukemia. Uracil mustard is not effective in acute lymphomas.

Hypersensitivity to tegafur or uracil; patient take sorivudine

X

It is not known if fluorouracil is excreted in human breast milk or if it will harm your nursing baby.

The toxicity profile of tegafur differs from 5-fluorouracil; nausea, vomiting, stomatitis, diarrhea, skin rash, and neurotoxicity (dizziness, confusion, ataxia) are the most frequent adverse events, which are minimized by administration of the drug orally in continuous low-dose regimens. Bone marrow depression is the dose-limiting effect of uracil mustard therapy. At an accumulated dose of 1 mg/kg, the risk of irreversible bone marrow damage is high.

5-8 cap (tegafur 500-800mg, 300-350 mg/m2/day) PO in 2-3 divided doses